162 related articles for article (PubMed ID: 25387217)
21. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
22. Albiglutide: first global approval.
Poole RM; Nowlan ML
Drugs; 2014 Jun; 74(8):929-38. PubMed ID: 24861909
[TBL] [Abstract][Full Text] [Related]
23. Incretin therapies in the management of patients with type 2 diabetes mellitus and renal impairment.
Dejager S; Schweizer A
Hosp Pract (1995); 2012 Apr; 40(2):7-21. PubMed ID: 22615074
[TBL] [Abstract][Full Text] [Related]
24. Glycaemic efficacy of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors as add-on therapy to metformin in subjects with type 2 diabetes-a review and meta analysis.
Deacon CF; Mannucci E; Ahrén B
Diabetes Obes Metab; 2012 Aug; 14(8):762-7. PubMed ID: 22471248
[TBL] [Abstract][Full Text] [Related]
25. Randomized 52-week Phase 2 Trial of Albiglutide Versus Placebo in Adult Patients With Newly Diagnosed Type 1 Diabetes.
Pozzilli P; Bosi E; Cirkel D; Harris J; Leech N; Tinahones FJ; Vantyghem MC; Vlasakakis G; Ziegler AG; Janmohamed S
J Clin Endocrinol Metab; 2020 Jun; 105(6):. PubMed ID: 32219329
[TBL] [Abstract][Full Text] [Related]
26. Liraglutide: a review of the first once-daily GLP-1 receptor agonist.
Bode B
Am J Manag Care; 2011 Mar; 17(2 Suppl):S59-70. PubMed ID: 21517658
[TBL] [Abstract][Full Text] [Related]
27. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus.
Montanya E; Sesti G
Clin Ther; 2009 Nov; 31(11):2472-88. PubMed ID: 20109994
[TBL] [Abstract][Full Text] [Related]
28. The safety and tolerability of GLP-1 receptor agonists in the treatment of type 2 diabetes: a review.
Aroda VR; Ratner R
Diabetes Metab Res Rev; 2011 Sep; 27(6):528-42. PubMed ID: 21484979
[TBL] [Abstract][Full Text] [Related]
29. Incretin-based therapies--review of the physiology, pharmacology and emerging clinical experience.
Martin JH; Deacon CF; Gorrell MD; Prins JB
Intern Med J; 2011 Apr; 41(4):299-307. PubMed ID: 21299778
[TBL] [Abstract][Full Text] [Related]
30. Safety and efficacy of dulaglutide, a once weekly GLP-1 receptor agonist, for the management of type 2 diabetes.
Kuritzky L; Umpierrez G; Ekoé JM; Mancillas-Adame L; Landó LF
Postgrad Med; 2014 Oct; 126(6):60-72. PubMed ID: 25414935
[TBL] [Abstract][Full Text] [Related]
31. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
32. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
33. Albiglutide (Tanzeum) for Diabetes Mellitus.
Trietley G; Skef S
Am Fam Physician; 2017 Apr; 95(8):521-522. PubMed ID: 28409609
[No Abstract] [Full Text] [Related]
34. Liraglutide: once-daily GLP-1 agonist for the treatment of type 2 diabetes.
Ryan GJ; Hardy Y
J Clin Pharm Ther; 2011 Jun; 36(3):260-74. PubMed ID: 21545609
[TBL] [Abstract][Full Text] [Related]
35. Attempted suicide with liraglutide overdose did not induce hypoglycemia.
Nakanishi R; Hirose T; Tamura Y; Fujitani Y; Watada H
Diabetes Res Clin Pract; 2013 Jan; 99(1):e3-4. PubMed ID: 23149376
[TBL] [Abstract][Full Text] [Related]
36. [Treatment strategy for elderly diabetic patient with insulin or GLP-1 receptor agonist].
Ando Y
Nihon Rinsho; 2013 Nov; 71(11):1993-8. PubMed ID: 24397172
[TBL] [Abstract][Full Text] [Related]
37. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
38. Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
Peterson G
Ann Med; 2012 Jun; 44(4):338-49. PubMed ID: 22530845
[TBL] [Abstract][Full Text] [Related]
39. Clinical pharmacology of incretin therapies for type 2 diabetes mellitus: implications for treatment.
Neumiller JJ
Clin Ther; 2011 May; 33(5):528-76. PubMed ID: 21665041
[TBL] [Abstract][Full Text] [Related]
40. Physiological mechanisms for the increase in renal solute-free water clearance by a glucagon-like peptide-1 mimetic.
Kutina AV; Marina AS; Shakhmatova EI; Natochin YV
Clin Exp Pharmacol Physiol; 2013 Aug; 40(8):510-7. PubMed ID: 23692186
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
